科伦博泰生物-B(06990.HK) 公布,创新药物SKB445的新药临床试验申请已获国家药品监督管理局药品审评中心批准。SKB445是一款由公司针对靶点生物学特点,利用OptiDC平台技术研发的具有自主知识产权的新型ADC药物。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-20 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.